# F. Stephen Hodi

Source: https://onco.cc/people/f-stephen-hodi/  
OnCo record `f-stephen-hodi` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

First author of the 2010 ipilimumab trial that proved immunotherapy could extend survival in melanoma.

## Summary

F. Stephen Hodi is Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber Brigham Cancer Center. He is known as first author of the 2010 phase 3 ipilimumab trial that opened the checkpoint-inhibitor era in melanoma, and later for the long-term follow-up of nivolumab plus ipilimumab in CheckMate 067. His selected papers report ipilimumab in metastatic melanoma and the long-term results of nivolumab with or without ipilimumab in advanced melanoma. He now directs Dana-Farber's immuno-oncology centre and continues to work on CTLA-4 and PD-1 blockade.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Melanoma Center and Center for Immuno-Oncology
- Specialisms: Melanoma; Checkpoint inhibitors; Immuno-oncology

## Sources

- Dana-Farber profile: https://www.dana-farber.org/find-a-doctor/f-stephen-hodi
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Hodi%20FS%5BAuthor%5D

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/), [Society for Immunotherapy of Cancer](https://onco.cc/institutions/sitc/)
- trials: [CheckMate 067](https://onco.cc/trials/checkmate-067/)
- key papers: [CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma](https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/), [Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma](https://onco.cc/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/)

---
JSON: https://onco.cc/api/v1/entities/f-stephen-hodi.json